New Hope for Parkinson's: How a Common Drug Could Reduce Dyskinesia
Discover how Vilazodone, originally developed for depression, is showing promise in reducing L-dopa-induced dyskinesia, a common side effect of Parkinson's disease treatment. This article explores the science, the potential benefits, and what it means for the future of Parkinson's care.